Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two genes eyed as hidden drivers of diabetes risk in obesity

NCT ID NCT00422006

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers want to know whether two genes, PCSK9 and FXR, help cause the combination of insulin resistance and abnormal blood fats that often comes with obesity. The study enrolls 111 adults with a high body mass index who are scheduled for bariatric surgery. During surgery, doctors take small samples of liver, muscle, and fat tissue. The team then measures how active those genes are and looks for links to insulin resistance, fatty liver disease, and gene variations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the genes PCSK9 and FXR turn out to drive insulin resistance and abnormal blood fats in obesity, this could point toward new drug targets for those conditions.
What could go wrong
This is an observational study of 111 people, so it can show associations but not prove cause and effect. Any findings may not apply to people who are not obese or who have not had bariatric surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

111 people

The number who actually took part.

Start date

Feb 2008

Finished

Nov 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * corporal mass index \> 40 kg/m² or \> 35 kg/m² associated to a co-morbidity resistant to a diet * bariatric surgery planned * no lipid-lowering drugs during 4 weeks before surgery * no treatment by metformin during 4 weeks before surgery * no treatment by glitazones during 8 weeks before surgery * age of the patient between 18 and 65 years * consent form signed * patient with social insurance Exclusion Criteria: * age inferior to 18 years * women pregnant * coagulation troubles * surgery contraindicated * Chronic hepatitis B or C active * VIH infected * other chronic hepatic disease * patient with dyslipidemia under lipid-lowering drugs in secondary prevention of a cardiovascular pathology * Type 2 diabetes under insulinosensitivator treatments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • CHU de Nantes

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.